Procter & Gamble seeks approval of Teva OTC takeover

Published: 12-Nov-2012
Finance Pharmaceutical

EC competition department will decide this month whether to clear acquisition


The European Commission competition department will decide this month (November) whether to clear Procter & Gamble’s acquisition of a second tranche of the over-the-counter (OTC) pharmaceutical business from Israel’s Teva Pharmaceuticals.

Procter & Gamble bought OTC services from Teva last year and now wants to buy more of the business, which Teva acquired from Cephalon in 2011.

  • Companies:
  • Teva
  • Procter and Gamble
See more

You may also like

Manufacturing

Europe’s generic medicines are disappearing, study finds

Read more
Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  3. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
  4. Tower Cold Chain’ industry-first shipping container design The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
  5. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Manufacturing

Teva Pharmaceuticals gives a look into each step of sterile medicine production

Teva Pharmaceuticals has released a video showing production steps at a site that manufactures 480 million doses a year
Research & Development

Teva completes facilities purchase in Pennsylvania

Investment will see the Israeli drug-maker set up a Research & Development campus in the US
Manufacturing

Teva signs deal for ‘Digital Twins’ to improve production

The three-year deal with Insilico will aim to transform data generated every day into measurable improvements to production processes
Media

QuintilesIMS and Teva UK win award for harmonised data analytics

This BHBIA “Excellence in Business Analytics” award also includes recognition of the advanced marketing insight programme
Regulatory

Patent battle for Aloxi in the US

Helsinn Healthcare and Eisai fall foul of reversed court decision regarding Teva Pharmaceuticals and Aloxi patent for the US market
Pharmaceutical

Teva sells UK and Ireland Actavis assets and operations

The buyer Accord Healthcare, a subsidiary of Intas Pharmaceuticals, will takeover the Barnstaple manufacturing plant
Subscribe now